Narrow your search

Library

KU Leuven (1)

Odisee (1)

Thomas More Kempen (1)

Thomas More Mechelen (1)

UCLL (1)

ULiège (1)

Vlerick Business School (1)

VIVES (1)

VUB (1)


Resource type

book (1)


Language

English (1)


Year
From To Submit

2023 (1)

Listing 1 - 1 of 1
Sort by

Book
Overcoming resistance to EGFR inhibitors in EGFR mutant NSCLC
Author:
ISBN: 9780128228340 0128228342 9780128228333 0128228334 Year: 2023 Publisher: London, England ; San Diego, California ; Cambridge, Massachusetts : Academic press,

Loading...
Export citation

Choose an application

Bookmark

Abstract

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer.

Keywords

Antineoplastic Agents. --- Carcinoma, Non-Small-Cell Lung. --- Genes, erbB-1. --- Anticancer Agents --- Antineoplastic Drugs --- Antineoplastics --- Antitumor Agents --- Antitumor Drugs --- Cancer Chemotherapy Agents --- Cancer Chemotherapy Drugs --- Chemotherapeutic Anticancer Agents --- Chemotherapeutic Anticancer Drug --- Anticancer Agent --- Antineoplastic --- Antineoplastic Agent --- Antineoplastic Drug --- Antitumor Agent --- Antitumor Drug --- Cancer Chemotherapy Agent --- Cancer Chemotherapy Drug --- Agent, Anticancer --- Agent, Antineoplastic --- Agent, Antitumor --- Agent, Cancer Chemotherapy --- Agents, Anticancer --- Agents, Antineoplastic --- Agents, Antitumor --- Agents, Cancer Chemotherapy --- Agents, Chemotherapeutic Anticancer --- Chemotherapy Agent, Cancer --- Chemotherapy Agents, Cancer --- Chemotherapy Drug, Cancer --- Chemotherapy Drugs, Cancer --- Drug, Antineoplastic --- Drug, Antitumor --- Drug, Cancer Chemotherapy --- Drug, Chemotherapeutic Anticancer --- Drugs, Antineoplastic --- Drugs, Antitumor --- Drugs, Cancer Chemotherapy --- Cytotoxins --- Interferon Inducers --- Anticarcinogenic Agents --- Genes, erbB1 --- c-erbB-1 Proto-Oncogenes --- v-erbB Oncogenes --- EGFR Genes --- Epidermal Growth Factor Receptor Genes --- Genes, EGFR --- c-erbB-1 Genes --- erbB-1 Genes --- v-erbB Genes --- EGFR Gene --- Gene, erbB1 --- c erbB 1 Genes --- c erbB 1 Proto Oncogenes --- c-erbB-1 Gene --- c-erbB-1 Proto-Oncogene --- erbB 1 Genes --- erbB-1 Gene --- erbB1 Gene --- erbB1 Genes --- v erbB Genes --- v erbB Oncogenes --- v-erbB Gene --- v-erbB Oncogene --- Nonsmall Cell Lung Cancer --- Carcinoma, Non-Small Cell Lung --- Non-Small Cell Lung Cancer --- Non-Small Cell Lung Carcinoma --- Non-Small-Cell Lung Carcinoma --- Carcinoma, Non Small Cell Lung --- Carcinomas, Non-Small-Cell Lung --- Lung Carcinoma, Non-Small-Cell --- Lung Carcinomas, Non-Small-Cell --- Non Small Cell Lung Carcinoma --- Non-Small-Cell Lung Carcinomas --- Lung Neoplasms --- Carcinoma, Small Cell --- Drug resistance. --- Lungs --- Cancer --- Chemotherapy. --- Resistance to drugs --- Pharmacology --- ErbB Receptors --- Drug Resistance

Listing 1 - 1 of 1
Sort by